US Pharma MarketingPharvaris
An extended-release version of deucrictibant reduced patients’ mean monthly attack rate by 83% compared to placebo, meeting the primary endpoint in a Phase 3 trial. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene…
Pharvaris claims it achieved “injectable-like efficacy” in a once-daily pill for a debilitating genetic disease.
The experimental drug, an extended-release version of deucrictibant, is designed to prevent swelling attacks in patients with a rare disease ...
Source: Endpoints News